Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate

Experimental Neurology

Volumn 240, Issue 1, 2013, Pages 130-144

  Aharoni, Rina ^a   Sasson, Efrat ^b   Blumenfeld Katzir, Tamar ^b   Eilam, Raya ^a   Sela, Michael ^a   Assaf, Yaniv ^c   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MRI Research and Consulting   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Diffusion tensor imaging (DTI); Experimental autoimmune encephalomyelitis (EAE); Glatiramer acetate (GA); Magnetic resonance imaging (MRI); Magnetization transfer ratio (MTR); Multiple sclerosis (MS); Neuroprotection

Indexed keywords

GLATIRAMER; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DISEASE MODEL; FEMALE; GRAY MATTER; HISTOGRAM; HISTOPATHOLOGY; IMAGE DISPLAY; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PRIORITY JOURNAL; WHITE MATTER;

ANIMALS; DIFFUSION TENSOR IMAGING; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PEPTIDES;

EID: 84870984675     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.11.004     Document Type: Article

References (52)

1. Agosta F., Rovaris M., Pagani E., Sormani M.P., Comi G., Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8years later in patients with multiple sclerosis. Brain 2006, 129:2620-2627.
2. Aharoni R. Immunomodulatory drug treatment in multiple sclerosis. Expert Rev. Neurother. 2010, 10:1423-1436.
3. Aharoni R., Teitelbaum D., Leitner O., Meshorer A., Sela M., Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11472-11477.
4. Aharoni R., Kayhan B., Eilam R., Sela M., Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14157-14162.
5. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005, 25:8217-82128.
6. Aharoni R., Eilam R., Domev H., Labunsky G., Sela M., Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19045-19050.
7. Aharoni R., Herschkovitz A., Eilam R., Blumberg-Hazan M., Sela M., Bruck W., Arnon R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11358-11363.
8. Aharoni R., Eilam R., Stock A., Vainshtein A., Shezen E., Gal H., Friedman N., Arnon R. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J. Neuroimmunol. 2010, 225:100-111.
9. Aharoni R., Vainshtein A., Stock A., Eilam R., From R., Shinder V., Arnon R. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. J. Autoimmun. 2011, 37:228-241.
10. Azoulay D., Vachapova V., Shihman B., Miler A., Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol. 2005, 167:215-218.
11. Basser P.J., Pierpaoli C. A simplified method to measure the diffusion tensor from seven MR images. Magn. Reson. Med. 1998, 39:928-934.
12. Boretius S., Escher A., Dallenga T., Wrzos C., Tammer R., Bruck W., Nessler S., Frahm J., Stadelmann C. Assessment of lesion pathology in a new animal model of MS by multiparametric MRI and DTI. Neuroimage 2011, 59:2678-2688.
13. Bruck W. Evidence for primary neurodegeneration in MS. Mult. Scler. 2008, (Suppl. 1):9-13.
14. Budde M.D., Kim J.H., Liang H.F., Russell J.H., Cross A.H., Song S.K. Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed. 2008, 21:589-597.
15. Budde M.D., Xie M., Cross A.H., Song S.K. Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysis. J. Neurosci. 2009, 29:2805-2813.
16. Carter N.J., Keating G.M. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010, 70:1545-1577.
17. Celis J.E., Madsen P., Nielsen S., Celis A. Nuclear patterns of cyclin (PCNA) antigen distribution subdivide S-phase in cultured cells - some applications of PCNA antibodies. Leuk. Res. 1986, 10:237-249.
18. Cercignani M., Bozzali M., Iannucci G., Comi G., Filippi M. Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2001, 70:311-317.
19. Comi G., Filippi M., Wolinsky J.S. European/Canadian multicenter double-blind randomized placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 2001, 49:290-297.
20. Davies G.R., Ramio-Torrenta L., Hadjiprocopis A., Chard D.T., Griffin C.M., Rashid W., Barker G.J., Kapoor R., Thompson A.J., Miller D.H. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2004, 75:998-1002.
21. DeBoy C.A., Zhang J., Dike S., Shats I., Jones M., Reich D.S., Mori S., Nguyen T., Rothstein B., Miller R.H., Griffin J.T., Kerr D.A., Calabresi P.A. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain 2007, 130:2199-2210.
22. Dousset V., Grossman R.I., Ramer K.N., Schnall M.D., Young L.H., Gonzalez-Scarano F., Lavi E., Cohen J.A. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 1992, 182:483-491.
23. Farina C., Weber M.S., Meinl E., Wekerle H., Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 2005, 4:567-575.
24. Filippi M., Agosta F. Magnetic resonance techniques to quantify tissue damage, tissue repair, and functional cortical reorganization in multiple sclerosis. Prog. Brain Res. 2009, 175:465-482.
25. Filippi M., Rocca M., Barkhof B., Bruck W., Chen J.T., Comi G., DeLuca G., De Stefano N., Erickson B.J., Evangelou N., Fazekas F., Geurts J.J., Lucchinetti C., Miller D.H., Pelletier D., Popescu B.F., Lassmann H. Attendees of the correlation between pathological MRI findings in MS workshop. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012, 11:349-360.
26. Gareau P.J., Rutt B.K., Karlik S.J., Mitchell J.R. Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J. Magn. Reson. Imaging 2000, 11:586-595.
27. Geurts J.J., Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008, 7:841-851.
28. Kutzelnigg A., Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?. J. Neurol. Sci. 2006, 245:123-126.
29. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J. Neurol. Sci. 2008, 274:45-47.
30. Lassmann H., Bruck W., Lucchinetti F. The immunopathology of MS: an overview. Brain Pathol. 2007, 17:210-218.
31. Lessman V., Gottmann K., Malcangio M. Neurotrophin secretion: current facts and future prospect. Prog. Neurobiol. 2003, 69:341-374.
32. MacKay A., Laule C., Vavasour I., Bjarnason T., Kolind S., Madler B. Insights into brain microstructure from the T2 distribution. Magn. Reson. Imaging 2006, 24:515-525.
33. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., Reynolds R., Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
34. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transected neurites apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001, 50:389-400.
35. Phuttharak W., Galassi W., Laopaiboon V., Laopaiboon M., Hesselink J.R. ADC measurements in various patterns of multiple sclerosis lesions. J. Med. Assoc. Thai. 2006, 89:196-204.
36. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: revisions to the McDonald criteria. Ann. Neurol. 2011, 292-302.
37. Ramio-Torrenta L., Sastre-Garriga J., Ingle G.T., Davies G.R., Ameen V., Miller D.H., Thompson A.J. Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J. Neurol. Neurosurg. Psychiatry 2006, 77:40-45.
38. Ranjeva J.P., Audoin B., Au Duong M.V., Ibarrola D., Confort-Gouny S., Malikova I., Soulier E., Viout P., Ali-Chérif A., Pelletier J., Cozzone P. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am. J. Neuroradiol. 2005, 26:119-127.
39. Rausch M., Tofts P., Lervik P., Walmsley A., Mir A., Schubart A., Seabrook T. Characterization of white matter damage in animal models of multiple sclerosis by magnetization transfer ratio and quantitative mapping of the apparent bound proton fraction. Mult. Scler. 2009, 15:16-27.
40. Rocca M.A., Mastronardo G., Rodegher M., Comi G., Filippi M. Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. AJNR Am. J. Neuroradiol. 1999, 20:821-827.
41. Rovaris M., Judica E., Gallo A., Benedetti B., Sormani M.P., Caputo D., Ghezzi A., Montanari E., Bertolotto A., Mancardi G., Bergamaschi R., Martinelli V., Comi G., Filippi M. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5years. Brain 2006, 129:2628-2634.
42. Serres S., Anthony D.C., Anthony D.C., Jiang Y., Campbell S.J., Broom T.A., Khrapitchev A., Sibon N.R. Comparison of MRI signatures in pattern I and II multiple sclerosis models. NMR Biomed. 2009, 22:1014-1024.
43. Sormani M.P., Bruzzi P., Comi G., Filippi M. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Mult. Scler. 2005, 11:447-449.
44. Sun S.W., Liang H.F., Schmidt R.E., Cross A.H., Song S. Selective vulnerability of cerebral white matter in a murine model of multiple sclerosis detected using diffusion tensor imaging. Neurobiol. Dis. 2007, 28:30-38.
45. Teitelbaum D., Meshorer M., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1:242-248.
46. Trapp B.D., Nave K.A. Multiple sclerosis an immune or neurodegenerative disease. Annu. Rev. Neurosci. 2008, 31:247-269.
47. Verhoye M.R., Gravenmade E.J., Raman E.R., Van Reempts J., Van der Linden A. In vivo noninvasive determination of abnormal water diffusion in the rat brain studied in an animal model for multiple sclerosis by diffusion-weighted NMR imaging. Magn. Reson. Imaging 1996, 14:521-532.
48. Vigeveno M.R., Wiebenga O.T., Wattjes M.K., Geurts J.J.G., Barkhof F. Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. J. Magn. Reson. Imaging 2012, 36:1-19.
49. Vrenken H., Pouwels P.J., Geurts J.J., Knol D.L., Polman C.H., Barkhof F., Castelijns J.A. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J. Magn. Reson. Imaging 2006, 23:628-636.
50. Whittall K.P., MacKay A.L., Graeb D.A., Nugent R.A., Li D.K., Paty D.W. In vivo measurement of T2 distributions and water contents in normal human brain. Magn. Reson. Med. 1997, 37:34-43.
51. Wolff S.D., Balaban R.S. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn. Reson. Med. 1989, 10:135-144.
52. Zivadinov R., De Masi R., Nasuelli D., Bragadin L.M., Ukmar M., Pozzi-Mucelli R.S., Grop A., Cazzato G., Zorzon M. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology 2001, 43:272-278.